Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT103A in Newly Diagnosed High-Risk Multiple Myeloma
NCT05181501Phase 1Not yet recruiting
- Sponsor
- Reindeer Biotech
- Start
- Apr 2022
- Primary completion
- Apr 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of equecabtagene autoleucel in multiple myeloma (MM), sponsored by Reindeer Biotech. Primary endpoints: Proportion of Minimal Residual Disease (MRD)-negative subjects up to 2 years and Median Progression-Free Survival up to 2 years. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
equecabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05181501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05181501.